Compare ACCO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | TENX |
|---|---|---|
| Founded | 1893 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.7M | 317.8M |
| IPO Year | 2005 | 2001 |
| Metric | ACCO | TENX |
|---|---|---|
| Price | $3.83 | $12.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $29.67 |
| AVG Volume (30 Days) | ★ 926.4K | 629.9K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | ★ 9.26% | N/A |
| EPS Growth | ★ 141.51 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,524,700,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $0.89 | N/A |
| P/E Ratio | $19.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.81 | $5.34 |
| 52 Week High | $4.30 | $18.38 |
| Indicator | ACCO | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 44.63 |
| Support Level | $3.82 | $10.83 |
| Resistance Level | $4.20 | $14.15 |
| Average True Range (ATR) | 0.13 | 0.73 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 29.96 | 48.36 |
ACCO Brands Corp is a consumer, technology and business branded products company providing brands and product solutions used in schools, homes and at work. Its brands include At-A-Glance, Barrilito, Buro, Esselte, Five Star, Foroni, GBC, Hilroy, Kensington, Leitz, Mead, PowerA, Quartet, Rapid, Swingline and Tilibra. The Company's product categories include gaming and computer accessories, storage and organization, notebooks, shredding, laminating and binding machines, dry erase boards and do-it-yourself tools. The Company operates through two segments, Americas and International. Americas includes the U.S., Canada, Brazil, Mexico and Chile, and International includes EMEA, Australia, New Zealand and Asia. Its products are sold in the U.S., Europe, Australia, Canada, Brazil and Mexico.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.